NPC’s Dr. Graff to Discuss What Value Should Look Like at BIO Convention

What should value look like? This is the question Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council (NPC), and fellow panelists will explore during a session, “The Search for Value: Pricing, Patient Access and New Ways of Thinking about Market Access,” at the 2016 BIO International Convention on Tuesday, June 7 at 12:15 pm PT.

What should value look like? This is the question Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council (NPC), and fellow panelists will explore during a session, “The Search for Value: Pricing, Patient Access and New Ways of Thinking about Market Access,” at the 2016 BIO International Convention on Tuesday, June 7 at 12:15 pm PT.

Dr. Graff will explain how the growing availability of real-world evidence—through efforts  such as PCORnet, the National Patient-Centered Clinical Research Network, and the Food and Drug Administration’s Sentinel Initiative—enables a broader view of treatment benefits that matter to patients, and what this means for the biopharmaceutical industry, payers and patients.

She will be joined by:

  • Amy Bricker, vice president, supply chain strategy, Express Scripts, who will share what her company looks for in assessing value, how the company balances patient access and spend, trends in formulary management relative to maximizing value, and ideas on how life sciences can better address the value question.
  • Josh Ofman, MD, MSHS, senior vice president, global value, access & policy, Amgen, who will discuss how his company is responding to the changing marketplace, opportunities and challenges for the biopharmaceutical industry, and recommendations on how industry can think about this new environment.
  • Jane Horvath, market access lead, 3D Communications, who will moderate the session and ask the panelists to consider how patient-centeredness fits into drug development, formulary design, and outcomes assessment and research.

The panelists also will address implications of new value assessment frameworks, how payers and the biopharmaceutical industry view them, and whether budget impact assessments should be a component of assessing value.

Furthermore, they’ll discuss the future of indication-based pricing, performance-based contracts and their experience with these contracts, and how the rapid pace of medical innovation and marketplace competition affects biopharmaceutical’s pricing considerations and the payers’ view of price.

Register now to attend the conference, which will take place at the Moscone Center in San Francisco.